CVJ.F AVALA RES

Healthcare Pharmaceuticals Frankfurt Exchange
0.0005 EUR
Close of Nov 11, 2026
0.0002 0.0130
Market cap
EUR 830K
P/E
0.1x
P/B
0.05x
ROE
71.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is CVJ.F undervalued?

Graham number

The Graham number of AVALA RES cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AVALA RES fundamental analysis

No fundamental analysis for AVALA RES yet.

AVALA RES stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AVALA RES

Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company was founded in 2014 and is based in Mildura, Australia.

Full company profile